OncoGenex's lung cancer drug to enter midstage trial

04/15/2013 | Pharmaceutical Business Review Online

OncoGenex plans to initiate a midstage study to assess the efficacy of its experimental drug OGX-427, in combination with carboplatin and pemetrexed, in extending progression-free survival of previously untreated patients with advanced nonsquamous nonsmall-cell lung cancer. The trial will involve about 155 participants.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care